Advanced Solid Malignancies
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Advanced Solid Malignancies is an early-stage landscape with 7 programs across 32 companies. The most active players are Oneness Biotech Co., Ltd., AstraZeneca, Carrick Therapeutics Limited.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Oneness Biotech Co., Ltd.
1 program
AstraZeneca
3 programs
Carrick Therapeutics Limited
1 program
Fresenius Kabi Oncology Ltd.
1 program
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
1 program
Daiichi Sankyo
1 program
Pipeline
Programs by Phase
Analysis
Modality Breakdown
71%
Small molecule
5 of 7 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 7 classified programs, each share of the total. Modality classified for 88% of 8 pipeline programs.
Analysis
Trial Status
98
clinical trials
Clinical Trials
Trial Activity
98 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)